Meta-Analysis
Copyright ©The Author(s) 2021.
World J Hepatol. May 27, 2021; 13(5): 595-610
Published online May 27, 2021. doi: 10.4254/wjh.v13.i5.595
Table 1 Type of intervention and outcome of study



Technical success
Clinical success
Rate of early adverse events
Rate of late adverse events
Stent patency
Reintervention
Procedure-related mortality
Ref.
Design
Year
SIS
SBS
SIS
SBS
SIS
SBS
SIS
SBS
SIS
SBS
SIS
SBS
SIS
SBS
Lee et al[33]RCT201934/3432/3532/3429/354/344/356/348/35Median 253 d (28-420); SD 98; mean 253Median 262 d (9-455); SD 111.5; mean 26215/3412/350/340/35
Naitoh et al[30]Cohort201224/2425/2824/2424/281/243/282/248/28Median 104 d (20-600); SD 145; mean 207Median 155 d (15–881); SD 216.5; mean 155NANA0/240/28
Kim et al[31]Cohort201218/2215/19NANA5/226/1911/227/19NANANANANANA
Law et al[29]Cohort20137/717/17NANANANA0/70/17NANA3/79/170/70/17
Ishigaki et al[32]Cohort202040/4023/2437/4023/249/4011/244/403/24Median 169 d (108-445); SD 84.25; mean 169Median 205 d (85-NA); SD 24.39; mean 123.75NANANANA
Table 2 Risk of bias for ROBINS-I
Ref.
D1
D2
D3
D4
D5
D6
D7
Overall
Naitoh et al[30] 2012ModerateModerateLowLowLowModerateModerateModerate
Kim et al[31] 2012SeriousSeriousLowSeriousSeriousSeriousSeriousSerious
Law et al[29] 2013ModerateModerateLowLowModerateModerateSeriousModerate
Ishigaki et al[32] 2020ModerateModerateLowLowLowModerateModerateModerate
Table 3 Risk of bias for RoB2
Ref.D1D2D3D4D5Overall
Lee et al[33], 2019LowLowLowLowLowLow
Table 4 Description of bias for each outcome (GRADE)
Certainty assessment
Summary of findings
Participants (studies) follow up
Risk of bias
Inconsistency
Indirectness
Imprecision
Publication bias
Overall certainty of evidence
Study event rates (%)
Relative effect (95%CI)
Anticipated absolute effects
With SBS
With SIS
Risk with SBS
Risk difference with SIS
Early adverse events: Cohorts
157 (3 observational studies)Serious1Not seriousNot seriousNot seriousNoneModerate20/71 (28.2)15/86 (17.4)RR 0.54 (0.31 to 0.96)282 per 1.000130 fewer per 1.000 (from 194 fewer to 11 fewer)
Early adverse events: RCT
69 (1 RCT)Not seriousNot seriousNot seriousSerious2NoneModerate4/35 (11.4)4/34 (11.8)RR 1.03 (0.28 to 3.79)114 per 1.0003 more per 1.000 (from 82 fewer to 319 more)
Late adverse events: Cohorts
181 (4 observational studies)Serious1Not seriousNot seriousNot seriousNoneModerate18/88 (20.5)17/93 (18.3)RR 0.82 (0.46 to 1.47)205 per 1.00037 fewer per 1.000 (from 110 fewer to 96 more)
Late adverse events: RCT
69 (1 RCT)Not seriousNot seriousNot seriousSerious2NoneModerate8/35 (22.9)6/34 (17.6)RR 0.77 (0.30 to 1.99)229 per 1.00053 fewer per 1.000 (from 160 fewer to 226 more)
Procedural-related mortality: Cohorts
76 (2 observational studies)Serious1Not seriousNot seriousNot seriousNoneModerate0/45 (0.0)0/31 (0.0)Not pooledNot pooledNot pooled
Procedural-related mortality: RCT
69 (1 RCT)Not seriousNot seriousNot seriousNot seriousNoneHigh0/35 (0.0)0/34 (0.0)RR 0.00 (-0.05 to 0.05)0 per 1.000- per 1.000 (from 0 fewer to 0 fewer)
Technical success: Cohorts
181 (4 observational studies)Serious1Not seriousNot seriousNot seriousNoneModerate80/88 (90.9)89/93 (95.7)RR 1.06 (0.97 to 1.16)909 per 1.00055 more per 1.000 (from 27 fewer to 145 more)
Technical success: RCT
69 (1 RCT)Not seriousNot seriousNot seriousNot seriousNoneHigh32/35 (91.4)34/34 (100.0)RR 1.09 (0.97 to 1.22)914 per 1.00082 more per 1.000 (from 27 fewer to 201 more)
Clinical success: Cohort
116 (2 observational studies)Serious1Serious3Not seriousNot seriousNoneLow47/52 (90.4)61/64 (95.3)RR 1.05 (0.87 to 1.26)904 per 1.00045 more per 1.000 (from 118 fewer to 235 more)
Clinical success: RCT
69 (1 RCT)Not seriousNot seriousNot seriousNot seriousNoneHigh29/35 (82.9)32/34 (94.1)RR 1.14 (0.96 to 1.35)829 per 1.000116 more per 1.000 (from 33 fewer to 290 more)
Reintervention: Cohort
24 (1 observational study) Serious1Not seriousNot seriousSerious2NoneLow9/17 (52.9)3/7 (42.9)RR 0.81 (0.31 to 2.13)529 per 1.000101 fewer per 1.000 (from 365 fewer to 598 more)
Reintervention: RCT
69 (1 RCT)Not seriousNot seriousNot seriousNot seriousNoneHigh12/35 (34.3)15/34 (44.1)RR 1.29 (0.71 to 2.33)343 per 1.00099 more per 1.000 (from 99 fewer to 456 more)
Stent patency: Cohort
116 (2 observational studies)Serious1Not seriousNot seriousNot seriousNoneModerate5264-The mean stent patency: Cohort was 0MD 45.75 higher (18.92 higher to 72.58 higher)
Stent patency: RCT
69 (1 RCT)Not seriousNot seriousNot seriousNot seriousNoneHigh3534-The mean stent patency: RCT was 0MD 9 lower (58.49 lower to 40.49 higher)

  • Citation: de Souza GMV, Ribeiro IB, Funari MP, de Moura DTH, Scatimburgo MVCV, de Freitas Júnior JR, Sánchez-Luna SA, Baracat R, de Moura ETH, Bernardo WM, de Moura EGH. Endoscopic retrograde cholangiopancreatography drainage for palliation of malignant hilar biliary obstruction — stent-in-stent or side-by-side? A systematic review and meta-analysis. World J Hepatol 2021; 13(5): 595-610
  • URL: https://www.wjgnet.com/1948-5182/full/v13/i5/595.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v13.i5.595